<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01497808</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 06611</org_study_id>
    <nct_id>NCT01497808</nct_id>
  </id_info>
  <brief_title>RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA</brief_title>
  <official_title>RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine the maximum tolerated hypofractionated radiotherapy
      dose (MTD) to a solitary metastatic focus ('index lesion') when followed by ipilimumab, in
      metastatic melanoma patients without brain involvement The secondary objectives are to
      determine late toxicity, immune-related clinical responses and immune pharmacodynamic changes
      after hypofractionated radiotherapy followed by ipilimumab
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2011</start_date>
  <completion_date type="Actual">October 12, 2015</completion_date>
  <primary_completion_date type="Actual">December 29, 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants with adverse events</measure>
    <time_frame>after 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy</intervention_name>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patient &gt; 18 years old

          -  Histologically confirmed diagnosis of melanoma

          -  Previously treated or previously untreated metastatic melanoma by AJCC staging
             criteria

          -  Presence of an index lesion &gt; 1 cm amenable to hypofractionated radiotherapy and at
             least one other additional lesion that can be followed for response using RECIST
             criteria

          -  ECOG Performance status 0 or 1

          -  Signed informed consent document

          -  Ability to tolerate stereotactic body radiation therapy (e.g. lie flat and hold
             position for treatment)

        Exclusion Criteria

          -  Prior systemic therapy within 14 days of study enrollment. Patients must be adequately
             recovered from prior systemic therapy side effects as deemed by the PI.

          -  Clinical contraindication to stereotactic body radiotherapy (e.g. active systemic
             sclerosis, active inflammatory bowel disease if bowel is within target field, etc)

          -  Presence or history of central nervous system metastasis (including brain)

          -  Long-term use of systemic corticosteroids

          -  Prior RT that precludes the delivery of hypofractionated radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Maity, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the Universirty of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 13, 2011</study_first_submitted>
  <study_first_submitted_qc>December 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2011</study_first_posted>
  <disposition_first_submitted>April 13, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 13, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 15, 2020</disposition_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>previously untreated</keyword>
  <keyword>previously treated</keyword>
  <keyword>bone, lung, liver or subcutaneous involvement</keyword>
  <keyword>nodal involvement</keyword>
  <keyword>without evidence of brain involvement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

